MetaCap

Cardiol Therapeutics (CRDL) vs Fate Therapeutics (FATE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Cardiol Therapeutics (CRDL) over the past year, losing 10.8% versus a loss of 11.3%. Over five years, CRDL leads with a -60.1% price change compared with -98.3% for FATE. Fate Therapeutics is the larger company by market cap ($111.8 million vs $110.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDL-11.35%FATE-10.78%
+213%+95%-22%
Nov 21, 20251 yearNov 20, 2026
CRDL-57.92%FATE-98.36%
+34%-35%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDL versus FATE key metrics
MetricCRDLFATE
Share price$0.8626$0.919
Market cap$110.14M$111.82M
1-day change-2.28%-9.01%
YTD return-9.58%-6.22%
1-year return-11.35%-10.78%
5-year return-60.06%-98.25%
EPS (TTM)$-0.24$-1.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.65M
Revenue growth (YoY)—-51.24%
Net income (latest FY)—$-136.31M
Operating margin—-2222.45%
Net margin—-2051.08%
52-week high$2.34$3.23
52-week low$0.8417$0.90
Distance from 52-week high-63.14%-71.55%
Analyst consensusstrong_buybuy
Avg. price target upside+874.96%+522.42%
Average volume1.20M1.53M
Shares outstanding127.69M121.67M
Employees18161
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

CRDL vs FATE FAQ

Which is bigger, Cardiol Therapeutics or Fate Therapeutics?

Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $110.14M for Cardiol Therapeutics (CRDL).

Which stock has performed better over the past year, CRDL or FATE?

FATE returned -10.78% over the past 12 months, compared with -11.35% for CRDL (price return, excluding dividends). Past performance does not predict future results.

Are Cardiol Therapeutics and Fate Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons